A case-control study of use of postmenopausal female hormone supplements in relation to the risk of large bowel cancer

Nurhayati Adnan, Julie R. Palmer, Carol Louik, Samuel Shapiro, Lynn Rosenberg

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Postmenopausal female hormone use has been associated with a reduced risk of colon cancer. We assessed the relation of use of these supplements to the risk of large bowel cancer. The data were collected in a case-control study of large bowel cancer conducted in Massachusetts. Control subjects were matched to incident cases of carcinoma of the colon or rectum on age, gender, and town precinct. The analysis was restricted to women who experienced a natural menopauser or had had a hysterectomy with or without removal of the ovaries (292 colon cancer cases and 112 rectal cancer cases and their matched controls). Use of female hormone supplements was associated with a decreased risk of colon cancer among recent users (odds ratio, 0.6; 95% confidence interval, 0.4-1.0) and long duration (5+ years) of use (odds ratio, 0.5; 95% confidence interval, 0.3-0.9). The association with long duration of use appeared to be independent of recency of use and screening practices and was apparent for late-stage cancer. Hormone supplement use was not associated with a reduced risk of rectal cancer. Our results add to the evidence for a decreased risk of colon cancer associated with use of female hormone supplements.

Original languageEnglish
Pages (from-to)443-447
Number of pages5
JournalCancer Epidemiology Biomarkers and Prevention
Volume9
Issue number4
Publication statusPublished - 1 Apr 2000

Fingerprint Dive into the research topics of 'A case-control study of use of postmenopausal female hormone supplements in relation to the risk of large bowel cancer'. Together they form a unique fingerprint.

Cite this